Chronic Kidney Disease

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

Eating patterns as a whole were more strongly associated with kidney health than intake of specific nutrients, researchers reported in the Journal of Renal Nutrition.

For nearly 2 decades, George L. Bakris, MD, was a pillar of the Cardiometabolic Health Congress, sharing his expertise, passion and unwavering dedication to advancing cardiometabolic health.

Neighborhood socioeconomic status was linked with incident heart failure among patients with chronic kidney disease who had more preserved kidney function, study results showed.

Remote BP monitoring and collaborative telehealth visits with a pharmacist improved BP control among patients at rural nephrology clinics and reduced hospitalization, a speaker reported.

DaVita has appointed David Maughan as its new chief operating officer, according to a company press release.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

Level of kidney function, rate of decline and type of renal disease are key factors influencing the decision to initiate kidney replacement therapy, whether dialysis or transplantation, for pediatric patients, according to study data. 

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.